HMGB1 and neoplasm: These results point to new possibilities: (1) ncRNAs associated with HMGB1 and ICD can serve as therapeutic targets for tumors; (2) cascade amplification of ICD effects can be achieved by targeting ncRNAs, thereby expanding tumor immunotherapy.